Hyundai Bioscience
Financials
Valuation Metrics
Hyundai Bioscience's Market Cap is ₩6273B. At end of 2025 it was ₩4792B. Ranked #403 of 2,436 in KR market (top 17%), #130 of 1,649 on KOSDAQ (top 8%), #9 of 57 in Household & Personal Products (top 16%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 627.29B KRW | KR#403/2,436 Sec#9/57 |
| Revenue | 3.13B KRW | KR#2,374/2,436 Sec#57/57 |
| Net Income | -21.30B KRW | KR—/2,436 Sec—/57 |
| Total Assets | 129.10B KRW | KR#1,574/2,436 Sec#31/57 |
| Net Assets | 111.98B KRW | KR#1,317/2,436 Sec#25/57 |
| Employees | 55 | KR#1,991/2,436 Sec#50/57 |
| Value | ||
| P/B | 5.60x | KR#2,256/2,436 Sec#54/57 |
| P/S | 200.20x | KR#2,399/2,436 Sec#57/57 |
| FCF Yield | -2.78% | KR—/2,436 Sec—/57 |
| Profitability | ||
| ROE | -19.02% | KR#2,056/2,436 Sec#51/57 |
| ROA | -16.50% | KR#2,196/2,436 Sec#54/57 |
| Op. Margin | -591.83% | KR#2,379/2,436 Sec#57/57 |
| Revenue Growth | -54.19% | KR#2,294/2,436 Sec#56/57 |
| Financial Health | ||
| Debt Ratio | 115.29% | KR#546/2,436 Sec#17/57 |
| Total Debt | 14.68B KRW | KR#1,487/2,436 Sec#31/57 |
| FCF | -17.47B KRW | KR#1,868/2,436 Sec#46/57 |
| Cash | 8.13B KRW | KR#1,790/2,436 Sec#37/57 |
| Current Ratio | 2.40x | KR#784/2,436 Sec#24/57 |
| Performance | ||
| 1Y Return | 11.68% | KR#613/2,436 Sec#9/57 |
| 1M Return | -19.15% | KR#2,163/2,436 Sec#55/57 |
| From 52W High | -69.77% | KR#2,141/2,436 Sec#51/57 |
| 1Y MDD | -73.65% | KR#2,085/2,436 Sec#46/57 |
| Trading | ||
| Volume | 1,252,823 shares | KR#127/2,436 Sec#1/57 |
| Foreign Own. | 7.91% | KR#570/2,436 Sec#14/57 |
| Per Share | ||
| EPS | -222 KRW | KR—/2,436 Sec—/57 |
| BPS | 1,160 KRW | KR#2,250/2,436 Sec#53/57 |
Company Info
Spun off from Hyundai Electronics in 2000, this bio pharmaceutical and cosmeceutical company was listed on KOSDAQ in 2002 and renamed Hyundai Bioscience in 2018. It is developing the broad-spectrum antiviral treatment CP-COV03 and anticancer drugs Polytaxel and Penicillium, while expanding its domestic and international markets with high-functional cosmetics Vitabrid C12 (exported to Japan) and Dr.BRID C. The company is securing new drug development pipelines in cooperation with C&Pharm and pursuing commercialization of clinical results through exchanges with international organizations. Hyundai Bio is headquartered in Gimcheon-si, Gyeongsangbuk-do.